{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:31:05Z","timestamp":1788690665245,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1097\/md.0000000000004796","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T06:44:44Z","timestamp":1477464284000},"page":"e4796","source":"Crossref","is-referenced-by-count":6,"title":["Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma"],"prefix":"10.1097","volume":"95","author":[{"given":"Uwe","family":"Wollina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Langner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Haroske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210309","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in Mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"R2-4-20210309","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1590\/abd1806-4841.20153768","article-title":"Primary cutaneous follicle center lymphoma simulating basal-cell carcinoma on the nasal ala","volume":"90","author":"Wanczinsnki","year":"2015","journal-title":"An Bras Dermatol"},{"key":"R3-4-20210309","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.dad.0000211514.98230.ba","article-title":"Primary cutaneous lymphoproliferative disorders with dual lineage rearrangement","volume":"28","author":"Kazakov","year":"2006","journal-title":"Am J Dermatopathol"},{"key":"R4-4-20210309","first-page":"109","article-title":"Liposomal cancer chemotherapy in dermatology: current status and future prospects","volume":"49","author":"Wollina","year":"2004","journal-title":"Indian J Dermatol"},{"key":"R5-4-20210309","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"R6-4-20210309","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.2005.06682.x","article-title":"Pegylated liposomal doxorubicin in stage IVB mycosis fungoides","volume":"153","author":"Di Lorenzo","year":"2005","journal-title":"Br J Dermatol"},{"key":"R7-4-20210309","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3324\/haematol.10879","article-title":"Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas","volume":"92","author":"Pulini","year":"2007","journal-title":"Haematologica"},{"key":"R8-4-20210309","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"R9-4-20210309","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdt480","article-title":"Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma","volume":"25","author":"Straus","year":"2014","journal-title":"Ann Oncol"},{"key":"R10-4-20210309","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0609.2008.01197.x","article-title":"Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies","volume":"82","author":"Pulini","year":"2009","journal-title":"Eur J Haematol"},{"key":"R11-4-20210309","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"R12-4-20210309","first-page":"429068","article-title":"Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a rapidly progressive variant of cutaneous T-cell lymphoma","volume":"2015","author":"Aderhold","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"R13-4-20210309","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.jaad.2013.06.012","article-title":"Primary cutaneous B cell lymphomas. Part I. Clinical features, diagnosis and classification","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R14-4-20210309","doi-asserted-by":"crossref","first-page":"343.e1","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B cell lymphomas. Part II. Therapy and future directions","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R15-4-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-014-2188-8","article-title":"Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients","volume":"94","author":"Xu","year":"2015","journal-title":"Ann Hematol"},{"key":"R16-4-20210309","first-page":"3019","article-title":"Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation","volume":"35","author":"Gatt","year":"2015","journal-title":"Anticancer Res"},{"key":"R17-4-20210309","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-8722-4-34","article-title":"Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy","volume":"4","author":"Kim","year":"2011","journal-title":"J Hematol Oncol"},{"key":"R18-4-20210309","first-page":"553","article-title":"Cutaneous peripheral T-cell lymphomas, unspecified\/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas","volume":"147","author":"Kempf","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"R20-4-20210309","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bjhh.2015.03.017","article-title":"Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations","volume":"37","author":"Lage","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R21-4-20210309","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ijrobp.2012.08.015","article-title":"Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified","volume":"85","author":"Zhang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-4-20210309","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann Hematol"},{"key":"R23-4-20210309","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:33:04Z","timestamp":1620959584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201610250-00004"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":22,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004796","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}